The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021
Life Sciences M&A Was Almost Half Of 2019’s Record
Executive Summary
COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.
You may also be interested in...
Deals Or No Deals, J.P. Morgan Sets The Tone For 2022
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’
Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.
How The Pandemic Changed Deal-Making Between Biotechs And Big Pharma
Speakers on a panel about health care deal-making discussed the influx of capital into biotech during the past two years, how that has impacted deal-making and whether those changes will last.